Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients.

about

Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients.

Item

http://www.wikidata.org/entity/Q41375534

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Association Between Background ...... apy in Breast Cancer Patients.

@en

type

Item

label

Association Between Background ...... apy in Breast Cancer Patients.

@en

prefLabel

Association Between Background ...... apy in Breast Cancer Patients.

@en

P1476

Association Between Background ...... apy in Breast Cancer Patients.

@en

P2093

Chao You

http://www.w3.org/2001/XMLSchema#string

Guangyu Liu

http://www.w3.org/2001/XMLSchema#string

Li Xie

http://www.w3.org/2001/XMLSchema#string

Luan Jiang

http://www.w3.org/2001/XMLSchema#string

Min He

http://www.w3.org/2001/XMLSchema#string

Weijun Peng

http://www.w3.org/2001/XMLSchema#string

Wenxiang Zhi

http://www.w3.org/2001/XMLSchema#string

Xiaoxin Hu

http://www.w3.org/2001/XMLSchema#string

Xuxia Shen

http://www.w3.org/2001/XMLSchema#string

Yajia Gu

http://www.w3.org/2001/XMLSchema#string

P2860

Changes in magnetic resonance mammography due to hormone replacement therapy

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

Redefining the target: chemotherapeutics as antiangiogenics.

Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers

Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.

Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?

Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer.

Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.

Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.

P304

786-792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TRANON.2017.07.005

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28806712

http://www.w3.org/2001/XMLSchema#string

P932

5554960

http://www.w3.org/2001/XMLSchema#string